Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.
Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H. Pascual J, et al. Among authors: eisenberger u. Transplant Rev (Orlando). 2019 Oct;33(4):191-199. doi: 10.1016/j.trre.2019.07.001. Epub 2019 Jul 23. Transplant Rev (Orlando). 2019. PMID: 31377099 Review.
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators. Budde K, et al. Among authors: eisenberger u. Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19. Lancet. 2011. PMID: 21334736 Clinical Trial.
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: eisenberger u. Am J Transplant. 2012 Jun;12(6):1528-40. doi: 10.1111/j.1600-6143.2012.03994.x. Epub 2012 Mar 5. Am J Transplant. 2012. PMID: 22642473 Free article. Clinical Trial.
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C; ZEUS Study Investigators. Lehner F, et al. Among authors: eisenberger u. Transpl Int. 2014 Nov;27(11):1192-204. doi: 10.1111/tri.12411. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 25070687 Free article. Clinical Trial.
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: eisenberger u. Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17. Am J Transplant. 2015. PMID: 25521535 Free article. Clinical Trial.
Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Wolters HH, Suwelack B, Klehr HU, Hauser IA, Stangl M, Nadalin S, Dürr M, Porstner M, May C, Wimmer P, Witzke O, Lehner F. Sommerer C, et al. Among authors: eisenberger u. Clin Nephrol. 2016 Apr;85(4):215-25. doi: 10.5414/CN108726. Clin Nephrol. 2016. PMID: 26932178 Clinical Trial.
Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.
Eisenberger U, Budde K, Lehner F, Sommerer C, Reinke P, Witzke O, Wüthrich RP, Stahl R, Heller K, Suwelack B, Mühlfeld A, Hauser IA, Nadalin S, Porstner M, Arns W; ZEUS Study Investigators. Eisenberger U, et al. BMC Nephrol. 2018 Jun 28;19(1):154. doi: 10.1186/s12882-018-0950-1. BMC Nephrol. 2018. PMID: 29954336 Free PMC article. Clinical Trial.
Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.
Sommerer C, Witzke O, Lehner F, Arns W, Reinke P, Eisenberger U, Vogt B, Heller K, Jacobi J, Guba M, Stahl R, Hauser IA, Kliem V, Wüthrich RP, Mühlfeld A, Suwelack B, Duerr M, Paulus EM, Zeier M, Porstner M, Budde K; ZEUS and HERAKLES study investigators. Sommerer C, et al. Among authors: eisenberger u. BMC Nephrol. 2018 Sep 19;19(1):237. doi: 10.1186/s12882-018-1031-1. BMC Nephrol. 2018. PMID: 30231851 Free PMC article.
Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies.
Subburayalu J, Dolff S, Xu S, Sun M, Lindemann M, Heinold A, Heinemann FM, Tervaert JWC, Eisenberger U, Korth J, Brinkhoff A, Kribben A, Witzke O, Wilde B. Subburayalu J, et al. Among authors: eisenberger u. Clin Immunol. 2021 May;226:108698. doi: 10.1016/j.clim.2021.108698. Epub 2021 Feb 24. Clin Immunol. 2021. PMID: 33639275
89 results